Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)

Daisuke Kikuchi, Taku Obara, Misaki Tokunaga, Makoto Shiozawa, Ai Takahashi, Misato Ito, Hiroaki Hino, Ryosuke Miura, Sachiko Hayakawa, Yoshiteru Watanabe

Research output: Contribution to journalArticlepeer-review

Abstract

We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.

Original languageEnglish
Article number102512
JournalAsian Journal of Psychiatry
Volume57
DOIs
Publication statusPublished - 2021 Mar

Keywords

  • Attention deficit hyperactivity disorder
  • Guanfacine
  • Pediatric
  • Prescription
  • Prevalence

ASJC Scopus subject areas

  • Psychology(all)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012–2018)'. Together they form a unique fingerprint.

Cite this